In the CANTOS trial, the administration of Canakinumab, an antagonist of IL-1beta, reduced the recurrence of cardiovascular events in patients with a history of myocardial infarction and CRP values > 2 mg/L as compared to a placebo. Here, IL1B is linked to myocardial infarction.